Audited Standalone Financial Results for year ended 31/03/2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cian Healthcare filed its audited standalone results for FY25, reporting total income of Rs. 3,113.50 lakhs, down sharply from Rs. 5,990.97 lakhs in FY24 — roughly a 48% drop. The company swung to a net loss of Rs. 1,965.65 lakhs, compared to a profit of Rs. 385.96 lakhs last year. Total assets stood at Rs. 14,267.51 lakhs with net worth of Rs. 4,215.51 lakhs. Exceptional items weighed on the results, including Rs. 1,109.01 lakhs for batch closures and Rs. 108.42 lakhs of sundry balances written off. The auditor issued a Disclaimer of Opinion, citing inability to verify loan balances (Rs. 3,311.14 lakhs), inventory value, GST credits, and going concern assumptions. The company remains under CIRP since June 2024, with the Resolution Professional in charge, and its wholly-owned subsidiary Dr. Smith's Biotech has also entered CIRP, delaying consolidated results.
Shareholders face significant risk — the company is in insolvency proceedings, posted a large loss, has defaulted on debt obligations, and has negative working capital. The auditor's disclaimer and the explicit going concern uncertainty mean the stock remains highly speculative until a resolution plan is approved.